HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

PMDA

Regulatory intelligence
PMDAsafety guidance54% confidence

[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.

Source: PMDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (copd) as Teva.

Regulatory Analysis

PMDA document relevant to the signal.

Supporting Context

Therapeutic area
Respiratory · Asthma/COPD
Sub-indication
COPD

Related signal: FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate

Source

View source document

Related Signal

Open signal — FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.